Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, Hirao T, Shibata K, Makari Y, Iijima S, Nishikawa H, Jungbluth AA, Nakamura Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Fujiwara S, et al. Among authors: makari y. Br J Cancer. 2013 Mar 19;108(5):1119-25. doi: 10.1038/bjc.2013.51. Epub 2013 Feb 12. Br J Cancer. 2013. PMID: 23403818 Free PMC article.
A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT.
Takiguchi S, Yamamoto K, Hirao M, Imamura H, Fujita J, Yano M, Kobayashi K, Kimura Y, Kurokawa Y, Mori M, Doki Y; Osaka University Clinical Research Group for Gastroenterological Study. Takiguchi S, et al. Gastric Cancer. 2012 Apr;15(2):198-205. doi: 10.1007/s10120-011-0098-1. Epub 2011 Oct 13. Gastric Cancer. 2012. PMID: 21993852 Clinical Trial.
Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H, Fujitani K, Matsuyama J, Akamaru Y, Tamura S, Endo S, Kimura Y, Makari Y, Tamura T, Sugimoto N, Sakai D, Tsujinaka T, Goto M, Kurokawa Y, Shimokawa T, Satoh T; Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG). Kawakami H, et al. Among authors: makari y. Int J Clin Oncol. 2020 Sep;25(9):1635-1643. doi: 10.1007/s10147-020-01711-z. Epub 2020 Jun 3. Int J Clin Oncol. 2020. PMID: 32494981 Clinical Trial.
Analysis of the risk factors for osteoporosis and its prevalence after gastrectomy for gastric cancer in older patients: a prospective study.
Kawabata R, Takahashi T, Saito Y, Nakatsuka R, Imamura H, Motoori M, Makari Y, Takeno A, Kishi K, Adachi S, Miyagaki H, Kurokawa Y, Yamasaki M, Eguchi H, Doki Y. Kawabata R, et al. Among authors: makari y. Surg Today. 2023 Apr;53(4):435-442. doi: 10.1007/s00595-022-02581-w. Epub 2022 Sep 6. Surg Today. 2023. PMID: 36066746
64 results